By Ellen Capon (Drug Target Review)2024-05-28T10:00:45
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-20T12:00:00Z
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2024-03-08T10:00:25
Sponsored by Molecular Devices
2023-04-12T15:28:08
Sponsored by nanoComposix
2024-01-19T07:40:55
Sponsored by Euretos
2025-05-14T14:30:00
Sponsored by Abzena
2025-09-18T12:00:00
Sponsored by Benchling
Site powered by Webvision Cloud